RxDoctor Payments Data

Susan King, MD

Otology & Neurotology · San Antonio, TXNPI 1396783528

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,383 of the $3,096 with a category attached, or 77.0%. 18 manufacturers reported payments, led by Cochlear Americas at 36.0% of the total.

$3,096in general payments, 2019–2025

Across 114 payments — averaging $27.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cochlear Americas$1K
  • AbbVie$730
  • Lundbeck LLC$376
  • Amgen$264
  • Pfizer$95
  • Teva Pharmaceuticals USA, Inc.$82
  • plus $435 from 12 others

What the payments were for

  • Travel & lodging$71323%
  • Food & beverage$2,38377%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,096 in reported general payments places this provider in the 70th percentile of 33 otology & neurotology providers in Texas.

See all otology & neurotology providers in Texas

Medicare billing

Part B allowed, 2024
$424,519
Medicare patients
1,333
Services billed
6,023

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate36$58,555
Aimovig AutoinjectorErenumab-Aooe36$30,730
Trokendi XrTopiramate21$26,521
Azelastine Hcl173$6,277
Epinephrine31$5,885
Fluocinolone Acetonide Oil87$4,068
Fluticasone Propionate180$3,363
Spironolactone259$2,614
Tizanidine Hcl227$2,428
Azelastine-FluticasoneAzelastine/Fluticasone18$2,409
Clonazepam109$2,255
ValiumDiazepam11$1,913
Montelukast Sodium110$1,350
Acetazolamide33$1,103
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid108$1,069

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$95$58,55536 claims
Supernus Pharmaceuticals, Inc.Trokendi Xr$66$26,52121 claims
Hikma Pharmaceuticals USAEpinephrine$59$5,88531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 33 otology & neurotology providers in Texas.

Other otology & neurotology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →